Stockscreener 앱 받기
3.09
10.43%
-0.36
시간 외 거래:
3.11
0.02
+0.65%
전일 마감가:
$3.45
열려 있는:
$3.43
하루 거래량:
143.74K
Relative Volume:
3.00
시가총액:
$5.13M
수익:
$2.00M
순이익/손실:
$-50.62M
주가수익비율:
-0.0739
EPS:
-41.8255
순현금흐름:
$-37.11M
1주 성능:
-10.69%
1개월 성능:
-23.89%
6개월 성능:
-58.80%
1년 성능:
-83.03%
1일 변동 폭
$3.00
$3.50
1주일 범위
$3.00
$3.6299
52주 변동 폭
$3.00
$71.50
바이오아틀라 Stock (BCAB) Company Profile
명칭
Bioatla Inc
전화
858-558-0708
주소
11085 TORREYANA ROAD, SAN DIEGO
Compare BCAB vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
3.09 | 5.61M | 2.00M | -50.62M | -37.11M | -41.83 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
바이오아틀라 Stock (BCAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-13 | 개시 | Rodman & Renshaw | Buy |
| 2025-08-13 | 다운그레이드 | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-11-13 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-09-15 | 개시 | JMP Securities | Mkt Outperform |
| 2022-05-05 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-03-21 | 개시 | H.C. Wainwright | Buy |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2021-06-28 | 개시 | ROTH Capital | Buy |
| 2021-05-05 | 재개 | Credit Suisse | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-01-11 | 개시 | BTIG Research | Buy |
| 2021-01-11 | 개시 | Credit Suisse | Outperform |
| 2021-01-11 | 개시 | JP Morgan | Overweight |
| 2021-01-11 | 개시 | Jefferies | Buy |
모두보기
바이오아틀라 주식(BCAB)의 최신 뉴스
BioAtla, Inc. Q2 2026: Revenue $6.5M, EPS $0.27— 10-Q Summary - TradingView
BioAtla (BCAB) turns Q2 2026 profit as cash falls and going concern risk emerges - Stock Titan
BioAtla, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Bioatla Inc (BCAB) Stock News Today - TradingKey
Bioatla Inc (BCAB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BioAtla (BCAB) Climbs 3.9% to $3.46 as Buyers Step In Near SupportTick Index - dars.gov.et
BCAB Q2'26 Earnings: EPS estimate is (8.50) USD - TradingView
BCAB|Bioatla Inc|Price:3.460|Chg%:+0.130 - TradingKey
Bioatla Inc (BCAB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Bioatla Inc (BCAB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bioatla Inc (BCAB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bioatla Inc (BCAB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Bioatla Inc (BCAB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
BioAtla, Inc. Revenue Breakdown – NASDAQ:BCAB - TradingView
Bioatla Inc (BCAB) Balance Sheet - TradingKey
Bioatla Inc (BCAB) Income Statement - TradingKey
TradingKey - TradingKey
BCAB|Bioatla Inc|Price:3.280|Chg%:-0.010 - TradingKey
BCAB|Bioatla Inc|Price:3.360|Chg%:-0.010 - TradingKey
Bioatla Inc (BCAB) Institutional Confidence - TradingKey
Bioatla Inc (BCAB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BioAtla Inc. (BCAB) Moves Higher: Biotech Stock Tests Key Resistance at $3.63Flat Correction - dars.gov.et
BioAtla Company Profile & Introduction - Moomoo
BioAtla Inc. (BCAB) Edges Lower Amid Consolidation, Testing Key Support LevelsNAAIM Exposure - dars.gov.et
BioAtla Shareholders Back Directors, Auditor and Pay Plan - The Globe and Mail
BioAtla, Inc. 8-K SEC Filing: Company Profile, Key Data, and Stock Information for July 2026 - Minichart
BCAB Q4 2025 Earnings: Substantial EPS Beat Signals Progress in Development PipelineAnalyst Earnings Estimate - po-news-eg.net
BCAB Q4 2025 Earnings: Narrower-than-Expected Loss Provides OptimismEarnings Miss Streak - DonanımHaber
BCAB Q4 2025 Earnings: Narrower-than-Expected Loss Drives Positive Investor ReactionPre-Earnings Setup - po-news-eg.net
BioAtla Inc. (BCAB) Q4 2025 Earnings: Narrower Net Loss Surpasses Expectations as Clinical Pipeline ProgressesBasic EPS Analysis - dars.gov.et
BCAB Q4 2025 Earnings: Narrower-Than-Expected Loss Surprises Markets as Stock DeclinesTax Rate Impact - dars.gov.et
BioAtla Inc. (BCAB) Surges Nearly 6% as Shares Test Key Resistance LevelStraddle Setup - dars.gov.et
BCAB Q4 2025 Earnings: Narrowing Losses Beat Street Estimates as Stock Rises 4%Annual Financial Report - po-news-eg.net
Price to sales forward of BioAtla, Inc. – NASDAQ:BCAB - TradingView
Enterprise value to revenue forward of BioAtla, Inc. – NASDAQ:BCAB - TradingView
BioAtla, Inc. Actuals & Estimates (NASDAQ:BCAB) - TradingView
BCAB Forecast — Price Target — Prediction for 2027 - TradingView
BioAtla: BioAtla, Inc.Reverse Split Option Symbol: BCAB New Symbol: BCAB1 - Moomoo
BioAtla Inc. (BCAB) Jumps Over 7% as Biotech Momentum BuildsValue Area Low - dars.gov.et
Bioatla Inc (BCAB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
BCAB Q4 2025 Earnings: Narrower-than-Expected Loss Surprises; Shares Edge HigherEarnings Surprise Report - dars.gov.et
BioAtla (BCAB) Q4 2025 Earnings: Narrowed Loss Beats Expectations as Stock AdvancesEarnings Expansion Phase - dars.gov.et
BioAtla Inc. (BCAB) Q4 2025 Earnings: Narrowed Loss and Positive Surprise Boost Investor Sentiment - dars.gov.et
BCAB Q4 2025 Earnings: Narrower-than-Expected Loss Drives Positive Stock ReactionEPS Consistency Score - newsline.com
BCAB Q4 2025 Earnings: Narrower Loss Surprises, Shares RiseLow Estimate Range - newsline.com
BioAtla Inc. (BCAB) Slips 2.5% as Shares Test Key Support ZoneBearish Pattern Stocks - newsline.com
BioAtla (BCAB) Slips 4.58% as Stock Nears Critical Support LevelTotal Put Call - newsline.com
BCAB Q4 2025 Earnings: Narrower-Than-Expected Loss Offers Partial Offset Amid Stock DeclineAnalyst Consensus Shift - newsline.com
BCAB Q4 2025 Earnings: Narrower-than-Expected Loss Highlights Cost Discipline Amid Pipeline ProgressROA Comparison - newsline.com
BioAtla (NASDAQ: BCAB) CFO logs non-sale share withholdings for RSU taxes - Stock Titan
BioAtla (BCAB) CMO has 494 shares withheld to cover RSU taxes - Stock Titan
바이오아틀라 (BCAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.07%
자본화:
|
볼륨(24시간):